Mirum Pharmaceuticals Appoints Eric Bjerkholt for the CFO position

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company committed to revolutionizing the treatment of rare diseases,  has announced the appointment of Eric Bjerkholt as Chief Financial Officer.

Chris Peetz, President and CEO of Mirum, expressed his confidence in Eric Bjerkholt’s capabilities, emphasizing his impressive track record in financial performance, business development, and operations management. Peetz highlighted the importance of Bjerkholt’s experience and leadership at a crucial phase of growth and global expansion for Mirum as the company continues to execute numerous initiatives within its rare disease franchises.

Eric Bjerkholt brings a wealth of business leadership experience from his roles in the biopharmaceutical industry. He joins Mirum from Chinook Therapeutics, Inc., where he served as CFO, overseeing various financial functions, including reporting, planning, budgeting, internal controls, investor relations, facilities, and information technology. Prior to his time at Chinook, Bjerkholt held the position of CFO at Aimmune Therapeutics, Inc., and he has had previous roles at companies such as Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Before entering the industry, he spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. Bjerkholt currently serves on the boards of CalciMedica, Inc., Cerus Corporation, and Surrozen, Inc. He holds an MBA from Harvard Business School and a Cand.Oecon degree from the University of Oslo in Norway.

Eric Bjerkholt expressed his excitement about joining Mirum, highlighting the company’s patient-centric approach, scientific rigor, and vibrant culture as critical elements for building a successful organization. He believes that Mirum is well-positioned for continued success and looks forward to contributing to the company’s growth and its mission to reach as many patients as possible worldwide with solutions addressing their medical needs.

In conjunction with his appointment, the Compensation Committee of Mirum’s Board of Directors approved an inducement grant, including 110,000 shares of common stock with an exercise price per share equal to Mirum’s closing stock price on September 11, 2023, and 55,000 restricted stock units under Mirum’s 2020 Inducement Plan. These awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements material to Mr. Bjerkholt’s employment.

Have you read?
Richest countries in the world by GDP per capita in 2023.
Countries With The Highest And Lowest Average Salaries, 2023.
Best Fashion Schools In The World.
Best Business Schools In The World.
The World’s Best CEOs And C-Suite Executives, 2023.